Although there is no clinical investigation on inhibition of HSF-1 and demonstration of enhanced efficacy of cancer treatment, many preclinical studies, including our recent study (11), show promise for the potential to use as HSF-1 inhibitor as novel chemotherapeutic agents. The gene discussed is HSF1; the disease is cancer.